Luminex Corp.

2013 News Releases

2014 | 2013 | 2012
DateTitle 
11/04/13Luminex Corporation Reports Third Quarter 2013 Results
AUSTIN, Texas, Nov. 4, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial and operating results for the third quarter ended September 30, 2013.  Highlights include the following: (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Consolidated third quarter revenue of $50.8 million Third quarter assay revenue of $16.1 million.  Infectious disease sales comprised approximately 64 percent of total assay sales, with genetic testing representing 3... 
Printer Friendly Version
10/29/13Luminex Corporation to Host Investor Event at Association for Molecular Pathology Annual Meeting
UNVEILING NEW SAMPLE-TO-ANSWER SYSTEM AUSTIN, Texas, Oct. 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will host an investor event in Phoenix, Arizona at the Association for Molecular Pathology Annual Meeting on Wednesday, November 13, 2013 beginning at 5:30 pm Mountain time. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Patrick J. Balthrop, president and chief executive officer, and other members of the executive managem... 
Printer Friendly Version
10/15/13Luminex Corporation Third Quarter Earnings Release Scheduled for November 4, 2013
AUSTIN, Texas, Oct. 15, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the third quarter of 2013 on Monday, November 4, 2013 after the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)   Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2013 on November 4, 2013, at 5:00 p.m. Eastern time. The conference c... 
Printer Friendly Version
09/23/13Luminex Corporation Receives FDA and European Clearance for a New Personalized Medicine Genotyping Assay, xTAG® CYP2C19 Kit
New Cytochrome P450 2C19 Assay Helps Physicians Optimize Individual Patient Care AUSTIN, Texas, Sept. 23, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a comprehensive genotyping assay, xTAG® CYP2C19 Kit.  This new test enables a personalized approach to aid physicians in determining patient treatment plans based on certain genetic variants of the P450 2C19 gene. (Logo: http://photos.... 
Printer Friendly Version
08/22/13Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
AUSTIN, Texas, Aug. 22, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Morgan Stanley Global Healthcare Conference to be held September 9 -11, 2013 in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 12:55 p.m. Eastern time (11:55 a.m. Central time) on Tuesday, September 10, 2013.  The presentation wi... 
Printer Friendly Version
08/07/13Luminex Corporation Announces Corporate Restructuring Actions to Drive Operational Excellence and Improve Focus on MDx Market
AUSTIN, Texas, Aug. 7, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced a restructuring plan focused on its Assay and Related Products ("ARP") Segment's Newborn Screening Group and its Brisbane, Australia office. The Company anticipates it will reduce its workforce by approximately 5% and close its Brisbane, Australia office.  This plan has been put in place to reduce expenses and better align the Company's resources with its focused growth initiatives.   As part of the re... 
Printer Friendly Version
07/29/13Luminex Corporation Reports Second Quarter 2013 Results
ACHIEVES MILESTONE SELLING 10,000TH MULTIPLEXING ANALYZER AUSTIN, Texas, July 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2013.  Financial and operating highlights include the following: Consolidated second quarter revenue was $54.3 million, a 12 percent increase over the second quarter of 2012 Second quarter assay revenue of $21.7 million, a 24 percent increase over the second quarter of 2012 C... 
Printer Friendly Version
07/22/13Luminex Corporation Achieves Milestone, Ships 10,000th Instrument
AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has passed a major milestone by shipping its 10,000th multiplexing instrument. This milestone was achieved by shipping a MAGPIX® instrument to Dr. Kimberle Chapin at the Rhode Island Hospital in Providence, R.I., the largest hospital and only Level I trauma center in the state. This MAGPIX instrument will be used initially for assay validation of Luminex's xTAG® Gastrointestinal Pathogen Panel.  ... 
Printer Friendly Version
07/15/13Luminex Corporation Receives FDA and European Clearance for an Updated Version of Its Comprehensive Genotyping Assay, xTAG® CYP2D6 Kit
Luminex Submits xTAG® CYP2C19 Kit to FDA for Review AUSTIN, Texas, July 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a new version of xTAG CYP2D6 Kit.  Additionally the company has submitted xTAG 2C19 Kit to FDA for review. Luminex is advancing its pharmacogenetic initiative for improved patient care. (Photo: http://photos.prnewswire.com/prnh/20130715/DA47259) (Logo: http://photos.prnewswire.com/prnh/20... 
Printer Friendly Version
07/08/13Luminex Corporation Second Quarter Earnings Release Scheduled for July 29, 2013
AUSTIN, Texas, July 8, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the second quarter of 2013 on Monday, July 29, 2013 after the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Management will hold a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2013 on July 29, 2013, at 5:00 p.m. Eastern time. The conference call will be ... 
Printer Friendly Version
06/11/13Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporation's xMAP Technology
Partnership Advances Pharmacogenomics for Improved Patient Care SEATTLE, June 11, 2013 /PRNewswire/ -- Natural Molecular Testing Corporation (Natural Molecular, NMTC), a privately-owned company providing groundbreaking clinical diagnostic molecular testing and services in the medical genomics field, announced today the launch of their laboratory developed comprehensive Personalized Medicine Panel. This cardiac panel, commercialized by Natural Molecular, is comprised of 42 targets and built ... 
Printer Friendly Version
05/28/13Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement
AUSTIN, Texas, May 28, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has extended their global supply and distribution agreement with EMD Millipore—the Life Science division of Merck KGaA, Darmstadt, Germany. This long-term agreement strengthens the partnership and facilitates development of life science and protein assays by EMD Millipore for Luminex's flexible platform. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) "We are very pleased to ex... 
Printer Friendly Version
05/07/13Luminex Corporation To Present At Upcoming Investment Conferences
AUSTIN, Texas, May 7, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at three upcoming investment conferences: The UBS Global Healthcare Conference on Tuesday, May 21 at 1pm ET in New York City The Jefferies 2013 Global Healthcare Conference on Tuesday, June 4 at 1:30pm ET in New York City, and The Goldman Sachs 34th Annual Global Healthcare Conference on Tuesday, June 11 at 1:20pm PT in Rancho Palos Verdes    The presentations w... 
Printer Friendly Version
04/29/13Luminex Corporation Reports First Quarter 2013 Results
GAINED FDA CLEARANCE FOR NOVEL GASTROINTESTINAL PATHOGEN PANEL AUSTIN, Texas, April 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2013.  Financial and operating highlights include the following: Consolidated first quarter revenue was $53.2 million, a 9 percent increase over the first quarter of 2012 Consolidated gross profit margin was 71 percent for the first quarter of 2013, compared to 69 percent... 
Printer Friendly Version
04/15/13Luminex Corporation Receives U.S. FDA Clearance for MAGPIX® Instrument with Novel xTAG® Gastrointestinal Pathogen Panel
Innovative multiplexing instrument for clinical laboratories with simultaneous testing for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test now available AUSTIN, Texas, April 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel (xTAG GPP). This is the first clinical assay to be c... 
Printer Friendly Version
04/08/13Luminex Corporation First Quarter Earnings Release Scheduled for April 29, 2013
AUSTIN, Texas, April 8, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the first quarter of 2013 on Monday, April 29, 2013 after the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2013 on April 29, 2013, at 5:00 p.m. Eastern time. The conference call will b... 
Printer Friendly Version
03/13/13Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimer’s Disease
Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Merck’s Lead Investigational Medicine for Alzheimer’s Disease WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Mar. 13, 2013-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck'... 
Printer Friendly Version
02/04/13Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
AUSTIN, Texas, Feb. 4, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and year ended December 31, 2012.  Financial and operating highlights include the following: Consolidated fourth quarter revenue of $55.5 million, a 16 percent increase over the fourth quarter of 2011; full-year 2012 revenue was $202.6 million, a 10 percent increase over 2011 Fourth quarter assay revenue of $23.8 million, a 45 percent increase over th... 
Printer Friendly Version
01/31/13Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
AUSTIN, Texas, Jan. 31, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Leerink Swann Global Healthcare Conference to be held February 13 -14, 2013, in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 11:30 a.m. Eastern time on Thursday, February 14, 2013.  The presentation will be webcast live an... 
Printer Friendly Version
01/16/13Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 4, 2013
AUSTIN, Texas, Jan. 16, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the fourth quarter of 2012 on Monday, February 4, 2013. A press release announcing the results is scheduled for release after the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and twelve months ended ... 
Printer Friendly Version
01/15/13Luminex Receives FDA Clearance for First Comprehensive Gastrointestinal Pathogen Infectious Disease Diagnostic in the United States
xTAG® Gastrointestinal Pathogen Panel (GPP) simultaneously tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test. AUSTIN, Texas, Jan. 15, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that it has received FDA clearance for its xTAG Gastrointestinal Pathogen Panel (GPP), the first comprehensive molecular diagnostic assay that tests for greater than 90% of bacterial, viral, and para... 
Printer Friendly Version
01/02/13Luminex Corporation To Present At JP Morgan Healthcare Conference
AUSTIN, Texas, Jan. 2, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 31st Annual JP Morgan Healthcare Conference to be held January 7 -10, 2013, in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, January 9, 2013.  The presentatio... 
Printer Friendly Version